Ardelyx appoints Mark Kaufmann as chief business officer
Role includes business development, licensing and strategic planning
Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.
‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.
Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.
Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.
Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.
You may also like
Manufacturing
PCI Pharma Services commences installation of sterile fill-finish and lyophilisation line
The Bedford, NH site will advance PCI's manufacturing capabilities with twin lyophilisers and a large-scale isolator filling line, making this the third sterile fill-finish facility built in the last three years
Hi Tech Manufacturing
Almost indestructible lab ware made of high-performance plastics - from BOLA
Fluoroplastics such as PTFE offer unique properties such as universal chemical resistance, near indestructibility, ease of cleaning, potential to be sterilised - making them ideal for the work in the lab
Manufacturing
From batch to continuous chemistry to continuous processing
The main challenge in many flow reactors lies in achieving a smooth and continuous flow within microchannels. Dec Group focuses on effectively transporting solid materials and engineering the flow to enhance chemical processes and increase their efficiency